159 related articles for article (PubMed ID: 9425397)
21. Dehydroepiandrosterone (DHEA) replacement reduces growth hormone (GH) dose requirement in female hypopituitary patients on GH replacement.
Brooke AM; Kalingag LA; Miraki-Moud F; Camacho-Hübner C; Maher KT; Walker DM; Hinson JP; Monson JP
Clin Endocrinol (Oxf); 2006 Nov; 65(5):673-80. PubMed ID: 17054472
[TBL] [Abstract][Full Text] [Related]
22. Insulin-like growth factor-I in growth hormone-deficient adults: relationship to population-based normal values, body composition and insulin tolerance test.
Svensson J; Johannsson G; Bengtsson BA
Clin Endocrinol (Oxf); 1997 May; 46(5):579-86. PubMed ID: 9231054
[TBL] [Abstract][Full Text] [Related]
23. An individualized GH dose regimen for long-term GH treatment in Japanese patients with adult GH deficiency.
Chihara K; Koledova E; Shimatsu A; Kato Y; Kohno H; Tanaka T; Teramoto A; Bates PC; Attanasio AF
Eur J Endocrinol; 2005 Jul; 153(1):57-65. PubMed ID: 15994746
[TBL] [Abstract][Full Text] [Related]
24. Serum lipid and leptin concentrations in hypopituitary patients with growth hormone deficiency.
Ozbey N; Algun E; Turgut AS; Orhan Y; Sencer E; Molvalilar S
Int J Obes Relat Metab Disord; 2000 May; 24(5):619-26. PubMed ID: 10849585
[TBL] [Abstract][Full Text] [Related]
25. Persisting effects on fasting glucose levels and insulin sensitivity after 6 months of discontinuation of a very low-dose GH therapy in adults with severe GH deficiency.
Yuen KC; Dunger DB
Clin Endocrinol (Oxf); 2006 May; 64(5):549-55. PubMed ID: 16649975
[TBL] [Abstract][Full Text] [Related]
26. Improvement in insulin sensitivity without concomitant changes in body composition and cardiovascular risk markers following fixed administration of a very low growth hormone (GH) dose in adults with severe GH deficiency.
Yuen KC; Frystyk J; White DK; Twickler TB; Koppeschaar HP; Harris PE; Fryklund L; Murgatroyd PR; Dunger DB
Clin Endocrinol (Oxf); 2005 Oct; 63(4):428-36. PubMed ID: 16181235
[TBL] [Abstract][Full Text] [Related]
27. Abnormal body composition and reduced bone mass in growth hormone deficient hypopituitary adults.
Beshyah SA; Freemantle C; Thomas E; Rutherford O; Page B; Murphy M; Johnston DG
Clin Endocrinol (Oxf); 1995 Feb; 42(2):179-89. PubMed ID: 7704962
[TBL] [Abstract][Full Text] [Related]
28. Two weeks of daily injections and continuous infusion of recombinant human growth hormone (GH) in GH-deficient adults: I. Effects on insulin-like growth factor-I (IGF-I), GH and IGF binding proteins, and glucose homeostasis.
Johansson JO; Oscarsson J; Bjarnason R; Bengtsson BA
Metabolism; 1996 Mar; 45(3):362-9. PubMed ID: 8606645
[TBL] [Abstract][Full Text] [Related]
29. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men.
Vittone J; Blackman MR; Busby-Whitehead J; Tsiao C; Stewart KJ; Tobin J; Stevens T; Bellantoni MF; Rogers MA; Baumann G; Roth J; Harman SM; Spencer RG
Metabolism; 1997 Jan; 46(1):89-96. PubMed ID: 9005976
[TBL] [Abstract][Full Text] [Related]
30. Dose-, IGF-I- and sex-dependent changes in lipid profile and body composition during GH replacement therapy in adult onset GH deficiency.
Abrahamsen B; Nielsen TL; Hangaard J; Gregersen G; Vahl N; Korsholm L; Hansen TB; Andersen M; Hagen C
Eur J Endocrinol; 2004 May; 150(5):671-9. PubMed ID: 15132723
[TBL] [Abstract][Full Text] [Related]
31. The metabolic effects of short-term administration of physiological versus high doses of GH therapy in GH deficient adults.
Yuen K; Cook D; Ong K; Chatelain P; Fryklund L; Gluckman P; Ranke MB; Rosenfeld R; Dunger D
Clin Endocrinol (Oxf); 2002 Sep; 57(3):333-41. PubMed ID: 12201825
[TBL] [Abstract][Full Text] [Related]
32. The effects of treatment and the individual responsiveness to growth hormone (GH) replacement therapy in 665 GH-deficient adults. KIMS Study Group and the KIMS International Board.
Bengtsson BA; Abs R; Bennmarker H; Monson JP; Feldt-Rasmussen U; Hernberg-Stahl E; Westberg B; Wilton P; Wüster C
J Clin Endocrinol Metab; 1999 Nov; 84(11):3929-35. PubMed ID: 10566630
[TBL] [Abstract][Full Text] [Related]
33. Effects of 7 years of growth hormone replacement therapy in hypopituitary adults.
Chrisoulidou A; Beshyah SA; Rutherford O; Spinks TJ; Mayet J; Kyd P; Anyaoku V; Haida A; Ariff B; Murphy M; Thomas E; Robinson S; Foale R; Johnston DG
J Clin Endocrinol Metab; 2000 Oct; 85(10):3762-9. PubMed ID: 11061536
[TBL] [Abstract][Full Text] [Related]
34. Effects of four years' treatment with biosynthetic human growth hormone (GH) on glucose homeostasis, insulin secretion and lipid metabolism in GH-deficient adults.
al-Shoumer KA; Gray R; Anyaoku V; Hughes C; Beshyah S; Richmond W; Johnston DG
Clin Endocrinol (Oxf); 1998 Jun; 48(6):795-802. PubMed ID: 9713570
[TBL] [Abstract][Full Text] [Related]
35. The effects of short-term administration of two low doses versus the standard GH replacement dose on insulin sensitivity and fasting glucose levels in young healthy adults.
Yuen K; Ong K; Husbands S; Chatelain P; Fryklund L; Gluckman P; Ranke M; Cook D; Rosenfeld R; Wass J; Dunger D
J Clin Endocrinol Metab; 2002 May; 87(5):1989-95. PubMed ID: 11994330
[TBL] [Abstract][Full Text] [Related]
36. Pre-treatment IGF-I level is the major determinant of GH dosage in adult GH deficiency.
Murray RD; Howell SJ; Lissett CA; Shalet SM
Clin Endocrinol (Oxf); 2000 May; 52(5):537-42. PubMed ID: 10792331
[TBL] [Abstract][Full Text] [Related]
37. Dose titration and patient selection increases the efficacy of GH replacement in severely GH deficient adults.
Murray RD; Skillicorn CJ; Howell SJ; Lissett CA; Rahim A; Shalet SM
Clin Endocrinol (Oxf); 1999 Jun; 50(6):749-57. PubMed ID: 10468947
[TBL] [Abstract][Full Text] [Related]
38. Metabolic effects of growth hormone administered subcutaneously once or twice daily to growth hormone deficient adults.
Laursen T; Jørgensen JO; Christiansen JS
Clin Endocrinol (Oxf); 1994 Sep; 41(3):337-43. PubMed ID: 7525120
[TBL] [Abstract][Full Text] [Related]
39. A therapeutic trial of growth hormone in hypopituitary adults and its influence upon continued prescription by general practitioners.
Davies JS; Obuobie K; Smith J; Rees DA; Furlong A; Davies N; Evans LM; Scanlon MF
Clin Endocrinol (Oxf); 2000 Mar; 52(3):295-303. PubMed ID: 10718827
[TBL] [Abstract][Full Text] [Related]
40. Final height data, body composition and glucose metabolism in growth hormone-treated short children born small for gestational age.
Hokken-Koelega AC; van Pareren Y; Sas T; Arends N
Horm Res; 2003; 60 Suppl 3():113-4. PubMed ID: 14671407
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
